**Outlook:**Sage Therapeutics Inc. Common Stock is assigned short-term Ba1 & long-term Ba1 estimated rating.

**Dominant Strategy :**Buy

**Time series to forecast n: 19 Feb 2023**for (n+3 month)

**Methodology :**Modular Neural Network (Market Direction Analysis)

## Abstract

Sage Therapeutics Inc. Common Stock prediction model is evaluated with Modular Neural Network (Market Direction Analysis) and Linear Regression^{1,2,3,4}and it is concluded that the SAGE stock is predictable in the short/long term.

**According to price forecasts for (n+3 month) period, the dominant strategy among neural network is: Buy**

## Key Points

- How do you decide buy or sell a stock?
- Which neural network is best for prediction?
- Is Target price a good indicator?

## SAGE Target Price Prediction Modeling Methodology

We consider Sage Therapeutics Inc. Common Stock Decision Process with Modular Neural Network (Market Direction Analysis) where A is the set of discrete actions of SAGE stock holders, F is the set of discrete states, P : S × F × S → R is the transition probability distribution, R : S × F → R is the reaction function, and γ ∈ [0, 1] is a move factor for expectation.^{1,2,3,4}

F(Linear Regression)

^{5,6,7}= $\begin{array}{cccc}{p}_{\mathrm{a}1}& {p}_{\mathrm{a}2}& \dots & {p}_{1n}\\ & \vdots \\ {p}_{j1}& {p}_{j2}& \dots & {p}_{jn}\\ & \vdots \\ {p}_{k1}& {p}_{k2}& \dots & {p}_{kn}\\ & \vdots \\ {p}_{n1}& {p}_{n2}& \dots & {p}_{nn}\end{array}$ X R(Modular Neural Network (Market Direction Analysis)) X S(n):→ (n+3 month) $R=\left(\begin{array}{ccc}1& 0& 0\\ 0& 1& 0\\ 0& 0& 1\end{array}\right)$

n:Time series to forecast

p:Price signals of SAGE stock

j:Nash equilibria (Neural Network)

k:Dominated move

a:Best response for target price

For further technical information as per how our model work we invite you to visit the article below:

How do AC Investment Research machine learning (predictive) algorithms actually work?

## SAGE Stock Forecast (Buy or Sell) for (n+3 month)

**Sample Set:**Neural Network

**Stock/Index:**SAGE Sage Therapeutics Inc. Common Stock

**Time series to forecast n: 19 Feb 2023**for (n+3 month)

**According to price forecasts for (n+3 month) period, the dominant strategy among neural network is: Buy**

**X axis: *Likelihood%** (The higher the percentage value, the more likely the event will occur.)

**Y axis: *Potential Impact%** (The higher the percentage value, the more likely the price will deviate.)

**Z axis (Grey to Black): *Technical Analysis%**

## IFRS Reconciliation Adjustments for Sage Therapeutics Inc. Common Stock

- If an entity originates a loan that bears an off-market interest rate (eg 5 per cent when the market rate for similar loans is 8 per cent), and receives an upfront fee as compensation, the entity recognises the loan at its fair value, ie net of the fee it receives.
- The requirements in paragraphs 6.8.4–6.8.8 may cease to apply at different times. Therefore, in applying paragraph 6.9.1, an entity may be required to amend the formal designation of its hedging relationships at different times, or may be required to amend the formal designation of a hedging relationship more than once. When, and only when, such a change is made to the hedge designation, an entity shall apply paragraphs 6.9.7–6.9.12 as applicable. An entity also shall apply paragraph 6.5.8 (for a fair value hedge) or paragraph 6.5.11 (for a cash flow hedge) to account for any changes in the fair value of the hedged item or the hedging instrument.
- Expected credit losses shall be discounted to the reporting date, not to the expected default or some other date, using the effective interest rate determined at initial recognition or an approximation thereof. If a financial instrument has a variable interest rate, expected credit losses shall be discounted using the current effective interest rate determined in accordance with paragraph B5.4.5.
- When measuring hedge ineffectiveness, an entity shall consider the time value of money. Consequently, the entity determines the value of the hedged item on a present value basis and therefore the change in the value of the hedged item also includes the effect of the time value of money.

*International Financial Reporting Standards (IFRS) adjustment process involves reviewing the company's financial statements and identifying any differences between the company's current accounting practices and the requirements of the IFRS. If there are any such differences, neural network makes adjustments to financial statements to bring them into compliance with the IFRS.

## Conclusions

Sage Therapeutics Inc. Common Stock is assigned short-term Ba1 & long-term Ba1 estimated rating. Sage Therapeutics Inc. Common Stock prediction model is evaluated with Modular Neural Network (Market Direction Analysis) and Linear Regression^{1,2,3,4} and it is concluded that the SAGE stock is predictable in the short/long term. ** According to price forecasts for (n+3 month) period, the dominant strategy among neural network is: Buy**

### SAGE Sage Therapeutics Inc. Common Stock Financial Analysis*

Rating | Short-Term | Long-Term Senior |
---|---|---|

Outlook* | Ba1 | Ba1 |

Income Statement | Baa2 | B3 |

Balance Sheet | Caa2 | B2 |

Leverage Ratios | B2 | Baa2 |

Cash Flow | B2 | Caa2 |

Rates of Return and Profitability | Caa2 | B3 |

*Financial analysis is the process of evaluating a company's financial performance and position by neural network. It involves reviewing the company's financial statements, including the balance sheet, income statement, and cash flow statement, as well as other financial reports and documents.

How does neural network examine financial reports and understand financial state of the company?

### Prediction Confidence Score

## References

- R. Sutton, D. McAllester, S. Singh, and Y. Mansour. Policy gradient methods for reinforcement learning with function approximation. In Proceedings of Advances in Neural Information Processing Systems 12, pages 1057–1063, 2000
- Artis, M. J. W. Zhang (1990), "BVAR forecasts for the G-7," International Journal of Forecasting, 6, 349–362.
- K. Boda, J. Filar, Y. Lin, and L. Spanjers. Stochastic target hitting time and the problem of early retirement. Automatic Control, IEEE Transactions on, 49(3):409–419, 2004
- Knox SW. 2018. Machine Learning: A Concise Introduction. Hoboken, NJ: Wiley
- M. Babes, E. M. de Cote, and M. L. Littman. Social reward shaping in the prisoner's dilemma. In 7th International Joint Conference on Autonomous Agents and Multiagent Systems (AAMAS 2008), Estoril, Portugal, May 12-16, 2008, Volume 3, pages 1389–1392, 2008.
- Çetinkaya, A., Zhang, Y.Z., Hao, Y.M. and Ma, X.Y., Is FFBC Stock Buy or Sell?(Stock Forecast). AC Investment Research Journal, 101(3).
- D. Bertsekas and J. Tsitsiklis. Neuro-dynamic programming. Athena Scientific, 1996.

## Frequently Asked Questions

Q: What is the prediction methodology for SAGE stock?A: SAGE stock prediction methodology: We evaluate the prediction models Modular Neural Network (Market Direction Analysis) and Linear Regression

Q: Is SAGE stock a buy or sell?

A: The dominant strategy among neural network is to Buy SAGE Stock.

Q: Is Sage Therapeutics Inc. Common Stock stock a good investment?

A: The consensus rating for Sage Therapeutics Inc. Common Stock is Buy and is assigned short-term Ba1 & long-term Ba1 estimated rating.

Q: What is the consensus rating of SAGE stock?

A: The consensus rating for SAGE is Buy.

Q: What is the prediction period for SAGE stock?

A: The prediction period for SAGE is (n+3 month)